Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Conmed (CNMD) over the last 4 years, with Q4 2025 value amounting to $19.4 million.

  • Conmed's Gains from Investment Securities rose 149532.4% to $19.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.0 million, marking a year-over-year increase of 15591.26%. This contributed to the annual value of $23.0 million for FY2025, which is 15591.26% up from last year.
  • Latest data reveals that Conmed reported Gains from Investment Securities of $19.4 million as of Q4 2025, which was up 149532.4% from $1.3 million recorded in Q3 2025.
  • In the past 5 years, Conmed's Gains from Investment Securities registered a high of $19.4 million during Q4 2025, and its lowest value of -$27.0 million during Q3 2024.
  • For the 4-year period, Conmed's Gains from Investment Securities averaged around -$1.4 million, with its median value being $1.2 million (2024).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 126153.85% in 2024, then skyrocketed by 149532.4% in 2025.
  • Over the past 4 years, Conmed's Gains from Investment Securities (Quarter) stood at $2.5 million in 2022, then tumbled by 472.12% to -$9.4 million in 2023, then soared by 113.01% to $1.2 million in 2024, then soared by 1495.32% to $19.4 million in 2025.
  • Its Gains from Investment Securities stands at $19.4 million for Q4 2025, versus $1.3 million for Q3 2025 and -$1.8 million for Q2 2025.